Ralinepag

About the Investigational Medication

Ralinepag is being evaluated in the clinical study to treat pulmonary arterial hypertension (PAH). Ralinepag is considered investigational because it is not approved by health authorities, including the U.S. Food and Drug Administration (FDA), for the treatment of PAH.

About Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a rare, progressive, life-threatening disorder characterized by increased pressure in the arteries that carry blood from the heart to the lungs. The increased pressure strains the heart, which can limit physical activity, result in heart failure and reduce life expectancy. Based on data from the Registry to EValuate Early And Long-term PAH disease management (REVEAL) of patients in the United States, there is an estimated five-year survival rate of 57% from diagnosis.

Phase 3 planning ongoing.

To Learn More, visit clinicaltrials.gov.